Zobrazeno 1 - 10
of 87 349
pro vyhledávání: '"Egfr"'
Publikováno v:
Zhongguo quanke yixue, Vol 27, Iss 35, Pp 4426-4434 (2024)
Background Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are one of the individualized targeted therapeutic options for patients with advanced EGFR mutated non-small cell lung cancer (NSCLC), which can significantly improve
Externí odkaz:
https://doaj.org/article/f0f5d8cc5e5c42f68c4254095dc12849
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-19 (2024)
Abstract Background There is a growing interest in utilizing a combination of brain radiotherapy (RT) and tyrosine kinase inhibitors (TKIs) for patients diagnosed with brain metastases (BM) in epidermal growth factor receptor (EGFR) mutation-positive
Externí odkaz:
https://doaj.org/article/6bd9a9f167024c33910c7a7c8db4c14b
Autor:
V. O. Varachev, O. Yu. Susova, A. A. Mitrofanov, G. S. Krasnov, D. R. Naskhletashvili, Yu. I. Ammour, S. D. Bezhanova, N. V. Sevyan, E. V. Prozorenko, A. Kh. Bekyashev, T. V. Nasedkina
Publikováno v:
Успехи молекулярной онкологии, Vol 11, Iss 3, Pp 68-78 (2024)
Introduction. Epidermal growth factor receptor (EGFR) is a transmembrane protein of the receptor tyrosine kinase family that is activated in various cancers (non-small cell lung cancer, colorectal cancer, head and neck tumors). In glial brain tumors,
Externí odkaz:
https://doaj.org/article/c74688be09cf44c580704332ebb593c1
Publikováno v:
Journal of the National Cancer Center, Vol 4, Iss 4, Pp 289-298 (2024)
Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced driver-negative non-small cell lung cancer (NSCLC). However, targeted therapy remains the preferred treatment for advanced driver-positive NSCLC, incl
Externí odkaz:
https://doaj.org/article/759bf25ca9734a26938c418738d8b658
Autor:
Sebastián Mas-Fontao, Esther Civantos, Nisa Boukichou, Juan A. Moreno, Jaakko Tuomilehto, Rafael Gabriel, Jesús Egido
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-15 (2024)
Abstract This sub-analysis of the ePREDICE trial, investigated the prevalence and determinants of renal complications, specifically glomerular hyperfiltration, albuminuria, and reduced kidney function, in individuals with prediabetes (PD). The cohort
Externí odkaz:
https://doaj.org/article/b6ce572f835843df964b82f9d1bc7837
Autor:
Ahmed Z. El-Hashim, Maitham A. Khajah, Khaled Y. Orabi, Sowmya Balakrishnan, Hanan G. Sary, Ahmad M. Barakat
Publikováno v:
Pharmaceutical Biology, Vol 62, Iss 1, Pp 326-340 (2024)
Context Asthma presents a global health challenge. The main pharmacotherapy is synthetic chemicals and biological-based drugs that are costly, and have significant side effects. In contrast, use of natural products, such as onion (Allium cepa L., Ama
Externí odkaz:
https://doaj.org/article/127ebbf353dd4b99ab74eeee4f30d609
Autor:
Jiali Wang, Xianhai He, Zhirong Jia, Aiwen Yan, Kang Xiao, Shuo Liu, Mengjun Hou, Yaling Long, Xuansheng Ding
Publikováno v:
Pharmaceutical Biology, Vol 62, Iss 1, Pp 33-41 (2024)
Context Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Gefitinib is a first-line treatment for NSCLC. However, its effectiveness is hindered by the development of drug resistance. At present, Shenqi Fuzheng injection (SFI)
Externí odkaz:
https://doaj.org/article/cdc0cd86e3184b7ab2c53f0fb2845907
Autor:
Nasim Sarrami, Bryce Nelson, Samantha Leier, John Wilson, Conrad Chan, Jalna Meens, Teesha Komal, Laurie Ailles, Melinda Wuest, Michael Schultz, Afsaneh Lavasanifar, Raymond M. Reilly, Frank Wuest
Publikováno v:
EJNMMI Radiopharmacy and Chemistry, Vol 9, Iss 1, Pp 1-13 (2024)
Abstract Background The objective of this research was the development and evaluation of 203Pb-labelled panitumumab (203Pb-PSC-panitumumab) as an immuno-SPECT radioligand for the detection of EGFR + head and neck squamous cell carcinoma (HNSCC) in a
Externí odkaz:
https://doaj.org/article/dbec871ee73f42fbb3a3914c8584d87c
Publikováno v:
Journal of Inflammation Research, Vol Volume 17, Pp 9725-9742 (2024)
Qiyu Jia,1,* Lu Liu,1,* Yunyuan Yu,2,* Wuhuzi Wulamu,1 Lin Jia,1 Bo Liu,1 Hao Zheng,3 Zhenlei Peng,1 Xiaogang Zhang,1 Ruixia Zhu2 1The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of Chin
Externí odkaz:
https://doaj.org/article/31778322d7e24cf48ba8b622d87e1c89
Publikováno v:
International Journal of General Medicine, Vol Volume 17, Pp 5503-5510 (2024)
Xiang Han,1 Yunhong You,1 Xiuhui Guo,2 Youxin Ji,1 Keke Nie1 1Department of Oncology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences (Qingdao Central Hospital), Qingdao, 266042, People’s Republic of China; 2Department of
Externí odkaz:
https://doaj.org/article/a4bc11e53e974b5dbabf473041dc81f1